The POSEIDON study showed significant improvements in patient quality of life with the Alfapump system. Sequana Medical plans to launch the Alfapump system commercially in the US in the second half of ...

Sequana Medical NV received premarket approval from the U.S. FDA for its Alfapump system to treat recurrent or refractory ascites due to liver cirrhosis. Data from the Poseidon pivotal study showed ...

The FDA’s approval of the PMA is based on the successful execution of Sequana Medical’s pivotal POSEIDON study, a landmark study across 18 centers in the US and Canada with a total of 69 ...

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES FOLLOWING LOAN CONVERSIONS Conversion of EUR 0.53 million under the Sensinnovat 2020 loan, EUR 1.28 million under the ...

Sequana Medical Announces US FDA Approval of alfapump ... MASH – Metabolic dysfunction-associated steatohepatitis 3 POSEIDON study results in SSED (PMA P230044, FDA approval letter on file ...

The FDA’s approval of the PMA is based on the successful execution of Sequana Medical’s pivotal POSEIDON study, a landmark study across 18 centers in the US and Canada with a total of 69 ...

Following positive data reported earlier this year from a Phase I/II trial, Sequana Medical has touted results from a study showing its device’s superiority in clearing sodium versus traditional ...

Ghent, Belgium - 13 January 2025 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "SequanaMedical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and ...